At a glance
ClinicalIndex Comparison Record- ✓Chronic atopic dermatitis with symptom onset ≥3 years prior to baseline and meets Hanifin and Rajka diagnostic criteria
- ✓Baseline EASI score ≥16, vIGA-AD score ≥3, and ≥10% body surface area involvement with AD
- ✓Baseline weekly average of daily Worst Pruritus Numeric Rating Scale ≥4
- ✓Candidate for systemic treatment: prior systemic AD therapy, inadequate topical response (TCS, TCI, or PDE-4 inhibitors), or topical treatments medically inadvisable
- ✕Two or more episodes of herpes zoster or one or more episodes of disseminated herpes zoster
- ✕One or more episodes of disseminated herpes simplex including eczema herpeticum
- ✕HIV infection (confirmed positive anti-HIV antibody test)
- ✕Active tuberculosis or meets TB exclusionary parameters
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3b/4 Randomized, Blinded, Treat-to-Target and Dose-Flexibility Study of Upadacitinib in Adult Subjects With Moderate to Severe Atopic Dermatitis
In Brief
A Phase 4 clinical trial evaluating Upadacitinib for Atopic Dermatitis. Completed, enrolled 461 participants across 106 sites in 18 countries.
Detailed Summary
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study evaluates the dosing flexibility of upadacitinib in adult participants with moderate to severe AD. Adverse events and change in the disease activity will be assessed. Upadacitinib is an approved drug for the treatment of moderate to severe/active immune-mediated inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis (UC), Crohn's Disease (CD), and AD. The study is comprised of a 35-day Screening Period, a 12-week double-blind period and a 12-week single-blind period. During the double-blind period, participants are placed in 1 of 2 groups, called treatment arms and will be randomized in a 1:1 ratio to receive upadacitinib. At 12 weeks during the single blind period, participants will be blinded to the upadacitinib dose based on their EASI response and reassigned to in 1 of 4 arms. After the last study visit, there is a 30-day follow-up visit. Approximately 454 adult participants ages 18 to 64 with moderate to severe AD who are candidates for systemic therapy will be enrolled at up to 160 sites worldwide. The study is comprised of a 12-week double-blind period, followed by a 12-week single-blind period. Participants will receive upadacitinib oral tablets once daily for up to 24 weeks. There may be higher treatment burden for participants in this trial compared to their standard of care (due to study procedures). Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Study Details
Timeline
Interventions
Oral tablet